Case Report: Transient hypertension and myalgia following mavacamten therapy in a patient with hypertrophic obstructive cardiomyopathy. [PDF]
Front Cardiovasc MedPeng M, Fu Y, Qin C, Zhou S, Sun J.
europepmc +1 more source
Mavacamten in Symptomatic Hypertrophic Cardiomyopathy: A Paradigm Shift or Revolution? [PDF]
JACC AsiaHung CL, Liu YW, Wu YW.
europepmc +1 more source
Pharmacological increases in circulating ketones fail to alleviate the hypertrophic cardiomyopathy present in the Tafazzin knockdown mouse model of Barth syndrome. [PDF]
J Pharm Pharm SciShafaati T +14 more
europepmc +1 more source
Omecamtiv mecarbil, a cardiac myosin activator with potential efficacy in heart failure. [PDF]
Arch Med Sci Atheroscler DisKallash M, Frishman WH, Aronow WS.
europepmc +1 more source
Molecular Pathology of Cardiomyopathies: Bridging Morphology, Genomics, and Clinical Phenotypes. [PDF]
Curr Issues Mol BiolMarzullo A, Salzillo C.
europepmc +1 more source
Complete left bundle branch block resolution during treatment with Mavacamten: a case report of a first-in-class scenario. [PDF]
Eur Heart J Case RepMarchionni G +4 more
europepmc +1 more source
From tumor immunotherapy to myocardial injury: A mechanistic discussion of immune checkpoint inhibitor‑related myocarditis (Review). [PDF]
Mol Med RepDai L, Duan Y, Xiong Q.
europepmc +1 more source
Cardiogenic Shock in Hypertrophic Cardiomyopathy Treated With Mavacamten and Clarithromycin. [PDF]
JACC Case RepAlabdaljabar MS, Desai M, Geske JB.
europepmc +1 more source
Diagnostic Ambiguity in Apical Hypertrophic Cardiomyopathy: Case-Based Insights and Review of Evolving Criteria. [PDF]
JACC Case RepLi-Jedras M +5 more
europepmc +1 more source